---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-063974"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:13:35.881146+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib

## Summary
- Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.
- Raised $264M from healthcare specialist funds in 2025 via private placement ($124.4M) and ATM ($117.6M).
- R&D expenses Q4 2025 $25.9M (down 19% YoY); full year 2025 $109.8M (down 4% YoY).
- Rinzimetostat Phase 1b: 55% PSA50, 20% PSA90, 76% ctDNA reduction; favorable safety vs competitors.
- Enozertinib Phase 1b: 67% ORR in 1L EGFR exon20, 80% ORR in 1L EGFR PACC; 100% intracranial ORR.

## SEC filing metadata
- accession: 0001193125-26-063974
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/0001193125-26-063974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/oric-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-063974
- JSON: https://secwatch.observer/filing/0001193125-26-063974.json
- Plain text: https://secwatch.observer/filing/0001193125-26-063974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.